Examkin

Soru

Zorluk: OrtaMedical Literature and Drug Advertisement Interpretation

Match the following excerpted scenarios from medical literature and pharmaceutical advertisements with the most appropriate methodological or statistical concept.

  • A pharmaceutical advertisement claims a 50%50\% decrease in stroke risk, reflecting an absolute incidence drop from 2%2\% in the placebo group to 1%1\% in the treatment group.Framing effect utilizing Relative Risk Reduction (RRR)
  • A randomized controlled trial whose primary endpoint was not met reports a statistically significant mortality benefit (p=0.03p=0.03) in a small subgroup of patients with advanced disease.Increased risk of Type I error due to multiple comparisons
  • A non-inferiority trial for a new antibiotic concludes the drug is equally effective to standard therapy based exclusively on an intention-to-treat (ITT) analysis.Biasing the results toward the null, artificially favoring non-inferiority
  • An observational study using electronic health records reports higher mortality with a new heart failure drug, but the drug is preferentially prescribed to patients with more refractory symptoms.Confounding by indication skewing the safety profile

Cevap

The scenarios match their respective methodological flaws: the advertisement utilizes RRR framing, the subgroup analysis risks Type I error inflation, the ITT non-inferiority analysis biases toward the null, and the registry study reflects confounding by indication.
Each excerpt perfectly illustrates a common methodological flaw or promotional tactic encountered in medical literature. RRR is frequently used in advertising to inflate perceived benefit relative to ARR. Subgroup analyses in overall negative trials run a high risk of Type I error. ITT analyses in non-inferiority trials bias results towards the null, which inappropriately supports the trial's goal. Finally, observational registries are highly susceptible to confounding by indication.

Adım Adım Çözüm

1
Evaluate the pharmaceutical advertisement claim regarding stroke risk.
The 50%50\% decrease represents Relative Risk Reduction (RRR), derived from a 1%1\% Absolute Risk Reduction (ARR).
Recognizing the difference between RRR and ARR is crucial, as advertisements often use RRR for a framing effect to inflate perceived efficacy.
2
Assess the post-hoc subgroup analysis finding (p=0.03p=0.03) in a negative trial.
The finding is highly susceptible to being a false positive.
Analyzing multiple subgroups without statistical adjustment increases the cumulative risk of a Type I error.
3
Analyze the impact of using only an intention-to-treat (ITT) approach in a non-inferiority trial.
ITT biases the study results toward the null hypothesis.
In a non-inferiority framework, biasing toward the null brings the outcomes of the two groups closer together, which anti-conservatively favors concluding that the new drug is non-inferior.
4
Identify the primary bias in the observational registry of the heart failure drug.
The association with higher mortality is driven by patient baseline characteristics.
Confounding by indication occurs when sicker patients selectively receive the newer or more intensive therapy.

Anahtar Kavram

Identifying statistical bias, study design flaws, and misleading data representations in medical literature.
Bu soruyu puanla

Konular

Medical Literature and Drug Advertisement Interpretation

Bu konudan daha fazla soru